Recent cohort studies have indicated that DPP-4 inhibitors were associated with a reduced risk of melanoma but not non-melanoma skin cancer (14), while GLP-1 receptor agonists did not show any association with skin cancer (15) when compared with sulfonylureas. This evidence concerns the gene GLP1R and skin cancer.